Trade Repligen Corp - RGEN CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 1.25
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 175.17
• Open: 183.66
• 1-Year Change: 23.24%
• Day's Range: 172.38 - 183.66

Trade Repligen Corp - RGEN

About Repligen Corporation

Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Repligen Corporation revenues increased 83% to $670.5M. Net income increased from $59.9M to $128.3M. Revenues reflect Product revenue - Filtration products segment increase from $174.9M to $403.5M, Product revenue - Protein products segment increase of 53% to $123.7M, Europe segment increase of 83% to $254.8M, North America segment increase of 56% to $274.9M.

Equity composition

Common Stock $.01 Par, 01/11, 40M auth., 30,787,307 issd. Insiders & strategic holders own 13.21%. PO 5/91, 2M shares @ $12.50 by Lehman Bros. Public Offering 2/94, 2.9M shares @ $6 by Lehman Brothers.